Group 1 - The company has applied for and obtained invention patents related to the crystal forms and preparation methods of its psychiatric drugs, Buprenorphine and Midazolam [2] - However, the company has not obtained any composition patents for these products [2]

Core Viewpoint - The company has a subsidiary that holds the production approval for Palivizumab injection, which is used for the treatment of influenza A and B. However, due to multiple factors such as centralized procurement policies and changes in the competitive market environment, the current sales volume of Palivizumab injection is very low, and it does not have a significant impact on the company's overall revenue and operating performance [1]. Group 1 - The company’s subsidiary possesses the production approval for Palivizumab injection [1] - Palivizumab injection is indicated for the treatment of influenza A and B [1] - Sales volume of Palivizumab injection is currently very low [1] Group 2 - The low sales volume is influenced by centralized procurement policies and market competition changes [1] - The current sales situation does not significantly affect the company's overall revenue [1] - The company's operating performance remains largely unaffected by the low sales of Palivizumab injection [1]

Core Viewpoint - Fu'an Pharmaceutical experienced a decline of 1.27% in stock price on November 17, with a trading volume of 117 million yuan, indicating a challenging market environment for the company [1] Financing Summary - On November 17, Fu'an Pharmaceutical had a financing buy-in amount of 12.45 million yuan and a financing repayment of 16.83 million yuan, resulting in a net financing outflow of 4.38 million yuan [1] - The total financing and securities balance for Fu'an Pharmaceutical as of November 17 is 403 million yuan, which accounts for 7.24% of its circulating market value, indicating a high level of financing compared to the past year [1] - The company had no short-selling activity on November 17, with a short-selling balance of 0 shares, reflecting a low level of short interest [1] Business Performance Summary - As of October 31, Fu'an Pharmaceutical had 39,200 shareholders, an increase of 0.72% from the previous period, while the average circulating shares per person decreased by 0.71% to 24,700 shares [2] - For the period from January to September 2025, Fu'an Pharmaceutical reported a revenue of 1.315 billion yuan, a year-on-year decrease of 34.08%, and a net profit attributable to shareholders of 166 million yuan, down 44.87% year-on-year [2] - Since its A-share listing, Fu'an Pharmaceutical has distributed a total of 688 million yuan in dividends, with 202 million yuan distributed over the past three years [2] Shareholding Summary - As of September 30, 2025, Hong Kong Central Clearing Limited was the eighth largest circulating shareholder of Fu'an Pharmaceutical, holding 4.9804 million shares, which is a decrease of 470,000 shares from the previous period [2]

11月14日，福安药业大宗交易成交100万股，成交额423万元，占当日总成交额的3.55%，成交价4.23 元，较市场收盘价4.74元折价10.76%。 | 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | 2025-11-14 | 300194 | 福安药业 | 4.23 | 100.00 | 423.00 中国中金财富证券 | 中国中金财富证券 | | | | | | | 有限公司海南分公 | 有限公司海南分公 | | | | | | | 司 | TG | ...

Core Viewpoint - Fuan Pharmaceutical (300194) announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd., has received the GMP compliance certificate from the Philippines' Department of Health Food and Drug Administration [1] Group 1 - The GMP compliance certificate signifies that the subsidiary meets the Good Manufacturing Practice standards required for pharmaceutical production [1]

Core Insights - As of October 31, the number of shareholders for Fu'an Pharmaceutical reached 39,204 [2] Company Summary - Fu'an Pharmaceutical responded to investor inquiries on November 5 regarding its shareholder count [2]

Core Insights - Fu'an Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Qingyutang Pharmaceutical Co., Ltd., has received a GMP compliance certificate from the Philippines' Department of Health, indicating that its production quality management system meets local GMP requirements, which will positively impact the subsidiary's overseas market expansion [1] Group 1 - The GMP compliance certificate was issued for the production of small-volume injectables, including powder and water injections, as well as penicillin-based powder injections [2] - The certificate is valid until July 24, 2028, confirming that the facilities and operations comply with the current drug production quality management standards [2] - The certification process involved a thorough on-site inspection, affirming that the production, sterilization, packaging, labeling, and quality control processes meet the necessary regulatory standards [2]

Core Viewpoint - Fuan Pharmaceutical's subsidiary, Qingyutang Pharmaceutical, has received a GMP compliance certificate from the Philippines' Department of Health, indicating adherence to good manufacturing practices [1] Group 1 - Fuan Pharmaceutical's subsidiary, Qingyutang Pharmaceutical, is fully owned by the company [1] - The GMP compliance certificate is a significant regulatory achievement for the company, enhancing its credibility in the pharmaceutical industry [1] - This certification may open up new market opportunities for Qingyutang Pharmaceutical in the Philippines [1]

Core Viewpoint - Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Qingyutang Pharmaceutical Co., Ltd., has received a GMP compliance certificate from the Philippines' Food and Drug Administration [1] Group 1 - The GMP compliance certificate signifies that Qingyutang meets the necessary standards for good manufacturing practices, which is crucial for pharmaceutical companies operating in international markets [1] - This certification may enhance the company's credibility and facilitate its expansion into the Southeast Asian market [1]

Core Viewpoint - Fuan Pharmaceutical's subsidiary, Qingyutang Pharmaceutical, has received a GMP compliance certificate from the Philippines' Department of Health, indicating its adherence to good manufacturing practices [1] Group 1 - Fuan Pharmaceutical's subsidiary, Qingyutang Pharmaceutical, is recognized for its compliance with GMP standards [1] - The GMP compliance certificate is a significant regulatory achievement that may enhance the company's market presence in the Philippines [1]